1. Home
  2. BNY vs CRBU Comparison

BNY vs CRBU Comparison

Compare BNY & CRBU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo BlackRock New York Municipal Income Trust

BNY

BlackRock New York Municipal Income Trust

HOLD

Current Price

$10.22

Market Cap

245.0M

Sector

Finance

ML Signal

HOLD

Logo Caribou Biosciences Inc.

CRBU

Caribou Biosciences Inc.

HOLD

Current Price

$1.91

Market Cap

203.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BNY
CRBU
Founded
2001
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Trusts Except Educational Religious and Charitable
Medicinal Chemicals and Botanical Products
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
245.0M
203.9M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
BNY
CRBU
Price
$10.22
$1.91
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$9.33
AVG Volume (30 Days)
52.7K
1.3M
Earning Date
01-01-0001
11-12-2025
Dividend Yield
3.93%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$9,295,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$4.96
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$8.60
$0.66
52 Week High
$10.80
$3.54

Technical Indicators

Market Signals
Indicator
BNY
CRBU
Relative Strength Index (RSI) 52.61 45.15
Support Level $10.13 $1.75
Resistance Level $10.20 $1.97
Average True Range (ATR) 0.07 0.12
MACD 0.01 0.02
Stochastic Oscillator 67.37 66.20

Price Performance

Historical Comparison
BNY
CRBU

About BNY BlackRock New York Municipal Income Trust

Blackrock NY Municipal Income Tr investment objective is to provide shareholders with as high a level of current income exempt from U.S. federal income taxes and New York State and New York City personal income taxes as is consistent with its investment policies and prudent investment management.

About CRBU Caribou Biosciences Inc.

Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies. The company operates and manage business as one reportable operating segment, which is the business of developing a pipeline of allogeneic CAR-T and CAR-NK cell therapies. Geographically, it operates in United States and Rest of the World, of which United States derives maximum revenue.

Share on Social Networks: